SELLAS Life Sciences Group, Inc.
Biotechnology ResearchView the employees at
SELLAS Life Sciences Group, Inc.-
Mady Alnemy Administrative/Social Media Coordinator at SELLAS Life Sciences
-
Rising Star
John Burns Senior Vice President, Chief Financial Officer at Sellas Life Sciences-
New York, New York, United States Contact Info
-
Rising Star
Angela Pettit Associate Director, Finance at Sellas Life Sciences-
Portland, Oregon Metropolitan Area
-
Rising Star
James Dean Senior Director, Clinical Operations, SELLAS Life Sciences-
Trenton, New Jersey, United States
-
Top 5%
Dr. Angelos M. Stergiou, MD,ScD hc President, Chief Executive Officer, and Board Director at Sellas Life Sciences Group, Inc.-
New York, New York, United States
-
Rising Star
Overview
We are a late-stage clinical biopharmaceutical company focused on developing novel therapies for a broad range of cancer indications. SELLAS’ lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 (WT1) protein, which is present in an array of tumor types. Our second product candidate, GFH009, is a highly selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor licensed from GenFleet Therapeutics, which we hold the exclusive rights to for further development and commercialization of the asset across all therapeutic and diagnostic uses outside of greater China. GPS and GFH009 have potential as monotherapies, or in combination with other therapies, to address a broad spectrum of hematologic malignancies and solid tumor indications.
-